Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Orchard Therapeutics plc | ortx-ex322_8.htm |
| EX-31.2 - EX-31.2 - Orchard Therapeutics plc | ortx-ex312_14.htm |
| EX-31.1 - EX-31.1 - Orchard Therapeutics plc | ortx-ex311_16.htm |
| EX-23.1 - EX-23.1 - Orchard Therapeutics plc | ortx-ex231_556.htm |
| EX-21.1 - EX-21.1 - Orchard Therapeutics plc | ortx-ex211_6.htm |
| 10-K - 10-K - Orchard Therapeutics plc | ortx-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Orchard Therapeutics plc (the “Company”) for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 2, 2021 |
By: |
/s/ Bobby Gaspar |
|
|
|
Bobby Gaspar |
|
|
|
Chief Executive Officer |